viewOpen Orphan PLC

Open Orphan to consult on river blindness treatment trial

The study is evaluating an antibiotic, produced by AbbVie, for patients with Onchocerciasis, the second-most common cause of blindness due to infection

Abbvie - Open Orphan called to consult river blindness treatment trial

Open Orphan PLC (AIM:ORPH, FRA:CRO) secured a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness.

Its subsidiary Venn Life Sciences will provide Data Management & Biostatistics services to support the Phase II trial of an antibiotic drug candidate for Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research organisation developing new affordable and patient-friendly treatments for neglected patients around the world.

READ: Open Orphan says COVID-19 challenge trial wins support of influential medical journal

DNDi was founded in 2003 by Médecins Sans Frontières, the World Health Organisation and five international research institutions.

The trial is taking place in the Democratic Republic of Congo and is evaluating ABBV-4083, owned by AbbVie and licensed to DNDi, as a potential antibiotic treatment for patients with Onchocerciasis, the second-most common cause of blindness due to infection after trachoma.

ABBV-4083 was identified by a screening of anti-infective compounds led by the pharmaceutical company AbbVie and the anti-Wolbachia consortium A-WOL at the Liverpool School of Tropical Medicine.

The study has already started, the AIM-listed group noted.

"We are delighted to announce another contract win for the business which underpins our confidence in the continued growth we expect to see in 2021,” said Open Orphan’s executive chairman Cathal Friel.

“Our teams have a unique knowledge of multiple clinical data management systems and our team of biostatisticians have extensive experience to bring to bear on such studies. We're very proud to be working with DNDi to support their development of what could be a game-changing drug to help people affected by river blindness in some of the world's poorest nations."

Quick facts: Open Orphan PLC


Price: 25.5 GBX

Market Cap: £171.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


London's FTSE 100 opens lower despite a strong performance in Asia and...

FTSE 100 opened lower despite a strong performance in Asian markets overnight and US futures pointing up after Labor Day weekend. London’s leading index dropped 16 points to 7,171 in early trading. Hyundai Motor Group will offer the option to power passenger vehicles and commercial vans,...

1 week, 5 days ago

2 min read